Literature DB >> 2472056

Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model.

D Zagzag1, M Goldenberg, S Brem.   

Abstract

Because of the crucial role played by tumor neovascularization in contrast enhancement, we studied the CT imaging findings in a transplantable rabbit brain tumor, the VX2 carcinoma that induces angiogenesis and the breakdown of blood-brain barrier associated with contrast enhancement. Tumor detection by contrast enhancement followed the peak of angiogenesis. Inhibition of angiogenesis, by copper depletion and penicillamine, led to avascular tumors that lack contrast enhancement. Furthermore, there was no contrast enhancement in brain adjacent to the tumor of normocupremic rabbits or within the hypocupremic tumor, despite the breakdown of the blood-brain barrier, without the concomitant presence of angiogenesis. We conclude that contrast enhancement of intracranial tumors is dependent primarily on the proliferation of the microvasculature.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472056     DOI: 10.2214/ajr.153.1.141

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  15 in total

Review 1.  Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Authors:  B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

2.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

3.  Initial contact of glioblastoma cells with existing normal brain endothelial cells strengthen the barrier function via fibroblast growth factor 2 secretion: a new in vitro blood-brain barrier model.

Authors:  Keisuke Toyoda; Kunihiko Tanaka; Shinsuke Nakagawa; Dinh Ha Duy Thuy; Kenta Ujifuku; Kensaku Kamada; Kentaro Hayashi; Takayuki Matsuo; Izumi Nagata; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2013-02-06       Impact factor: 5.046

4.  Measurements of heterogeneity in gliomas on computed tomography relationship to tumour grade.

Authors:  Karoline Skogen; Balaji Ganeshan; Catriona Good; Giles Critchley; Ken Miles
Journal:  J Neurooncol       Date:  2012-12-06       Impact factor: 4.130

5.  Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumors.

Authors:  D Yoshida; Y Ikeda; S Nakazawa
Journal:  J Neurooncol       Date:  1993-05       Impact factor: 4.130

6.  Suppression of 9L gliosarcoma growth by copper depletion with copper-deficient diet and D-penicillamine.

Authors:  D Yoshida; Y Ikeda; S Nakazawa
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

7.  Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases.

Authors:  Frits Thorsen; Brett Fite; Lisa M Mahakian; Jai W Seo; Shengping Qin; Victoria Harrison; Sarah Johnson; Elizabeth Ingham; Charles Caskey; Terje Sundstrøm; Thomas J Meade; Patrick N Harter; Kai Ove Skaftnesmo; Katherine W Ferrara
Journal:  J Control Release       Date:  2013-10-29       Impact factor: 9.776

8.  Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice.

Authors:  R D Zhang; J E Price; T Fujimaki; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

9.  Anaplastic oligodendroglioma: advances and treatment options.

Authors:  Mairéad G McNamara; Solmaz Sahebjam; Warren P Mason
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.972

Review 10.  Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.

Authors:  Manabu Onishi; Kazuhiko Kurozumi; Tomotsugu Ichikawa; Isao Date
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-10-25       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.